Infliximab updated on 06-01-2019

Table   Graphic     exposition period:

Congenital malformations
Adverse outcome OR 95%CII2k No. casesNo. exposedpublication biasROBE-value
All congenital malformations (majors, minors, majors and minors, or unspecified)3.30 [1.43, 7.61]0%3 studies28161not evaluable ROB6.05 [2.21; .]
Major congenital malformations3.11 [1.32, 7.31]0%2 studies28158not evaluable ROB5.68 [1.98; .]

Growth parameters and prematurity
Adverse outcome OR 95%CII2k No. casesNo. exposedpublication biasROBE-value
Preterm (< 37 weeks)1.63 [0.06, 41.29]-1 study33not evaluable ROB-
Small for gestational age (weight)7.50 [0.46, 122.70]-1 study33not evaluable ROB-
Macrosomia (> 4000g)12.60 [0.20, 780.42]-1 study3not evaluable ROB-

Maternal consequences
Adverse outcome OR 95%CII2k No. casesNo. exposedpublication biasROBE-value
Caesarean--0 study-

Neonatal disorders
Adverse outcome OR 95%CII2k No. casesNo. exposedpublication biasROBE-value
Neonatal infections4.37 [1.30, 14.71]-1 study5237not evaluable ROB8.21 [1.92; .]
Neonatal disorders (as a whole)--0 study-
Neonatal medical care--0 study-

Intrauterine deaths
Adverse outcome OR 95%CII2k No. casesNo. exposedpublication biasROBE-value
Elective/induced termination of pregnancy3.40 [0.05, 219.14]-1 study3not evaluable ROB-
Early intrauterine deaths (< 22 weeks) / Spontaneous abortions4.00 [0.17, 95.76]-1 study23not evaluable ROB-
Intrauterine deaths (as a whole or unspecified)--0 study-
Late intrauterine deaths (> 22 weeks) / Stillbirths--0 study-
Therapeutic terminations of pregnancy--0 study-

Hide endpoints reported in only one study ...

- About - Master protocol - Browse exposition - RSS - Made with in Lyon - Contact us - Privacy policy - Licence Creative Commons